Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Kastrati, Irida ^a   Edirisinghe, Praneeth D ^a   Hemachandra, L P Madhubani P ^a   Chandrasena, Esala R ^a   Choi, Jaewoo ^a   Wang, Yue Ting ^a   Bolton, Judy L ^a   Thatcher, Gregory R J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; CATECHOL ESTROGEN; CELL MARKER; CYTOCHROME P450 1B1; ESTROGEN RECEPTOR; HISTONE DEACETYLASE INHIBITOR; NORARZOXIFENE; RALOXIFENE; UNCLASSIFIED DRUG; 8 OXO 7 HYDRODEOXYGUANOSINE; 8-OXO-7-HYDRODEOXYGUANOSINE; BENZOTHIOPHENE; BIOLOGICAL MARKER; CATECHOL DERIVATIVE; CYTOCHROME P450; DEOXYGUANOSINE; DESMETHYLARZOXIFENE; DRUG DERIVATIVE; ESTROGEN; PIPERIDINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTROPHILIC STRESS; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; METABOLITE; OXIDATIVE STRESS; UPREGULATION; ANIMAL; BIOSYNTHESIS; BREAST; CELL LINE; CELL TRANSFORMATION; CHEMISTRY; DNA ADDUCT; ENZYME INDUCTION; ENZYMOLOGY; EPITHELIUM CELL; FEMALE; HORSE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

ANIMALS; BIOLOGICAL MARKERS; BREAST; CATECHOLS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYTOCHROME P-450 ENZYME SYSTEM; DEOXYGUANOSINE; DNA ADDUCTS; ENZYME INDUCTION; EPITHELIAL CELLS; ESTROGENS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HORSES; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PIPERIDINES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES;

EID: 82255173834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027876     Document Type: Article

References (66)

1. Russo J, Hasan Lareef M, Balogh G, Guo S, et al. (2003) Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 87: 1-25.
2. Liehr JG, (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21: 40-54.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
4. Beral V, (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427.
5. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, et al. (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670-1674.
6. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647.
7. Cosman F, Lindsay R, (1999) Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 20: 418-434.
8. Conzen SD, (2003) Current status of selective estrogen receptor medulators (SERMs). Cancer Journal 9: 4-11.
9. Shang Y, Brown M, (2002) Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468.
10. Osborne CK, Zhao H, Fuqua SA, (2000) Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 18: 3172-3186.
11. Duong V, Bret C, Altucci L, Mai A, Duraffourd C, et al. (2008) Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 6: 1908-1919.
12. Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ, (2007) Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105: 297-309.
13. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, et al. (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086.
14. Tait L, Soule HD, Russo J, (1990) Ultrastructural and Immunocytochemical Characterization of an Immortalized Human Breast Epithelial-Cell Line, Mcf-10. Cancer Res 50: 6087-6094.
15. Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, et al. (1991) Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog 4: 25-35.
16. Shin SI, Freedman VH, Risser R, Pollack R, (1975) Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A 72: 4435-4439.
17. Russo J, Lareef MH, Tahin Q, Hu YF, Slater C, et al. (2002) 17Beta-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 80: 149-162.
18. Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, et al. (2010) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res.
19. Yu B, Dietz BM, Dunlap T, Kastrati I, Lantvit DD, et al. (2007) Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. Mol Cancer Ther 6: 2418-2428.
20. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, et al. (2006) The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res 12: 5902-5909.
21. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, et al. (2009) HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 8: 794-801.
22. Bicaku E, Marchion DC, Schmitt ML, Munster PN, (2008) Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 68: 1513-1519.
23. Lu F, Zahid M, Saeed M, Cavalieri EL, Rogan EG, (2007) Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J Steroid Biochem Mol Biol 105: 150-158.
24. Beis I, Newsholme EA, (1975) The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem J 152: 23-32.
25. Abul-Hajj YJ, Cisek PL, (1986) Regioselective reaction of thiols with catechol estrogens and estrogen-O-quinones. 25: 245-247.
26. Chen Z-H, Na H-K, Hurh Y-J, Surh Y-J, (2005) 4-Hydroxyestradiol induces oxidative stress and apoptosis in human mammary epithelial cells: possible protection by NF-kappaB and ERK/MAPK. Toxicology and applied pharmacology 208: 46-56.
27. Macmahon B, Feinleib M, (1960) Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst 24: 733-753.
28. Zhu BT, Liehr JG, (1996) Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin. Possible role in estradiol-induced tumorigenesis. J Biol Chem 271: 1357-1363.
29. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A, (1986) Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem 24: 353-356.
30. Li JJ, Li SA, (1987) Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc 46: 1858-1863.
31. Zhu BT, Bui QD, Weisz J, Liehr JG, (1994) Conversion of estrone to 2- and 4-hydroxyestrone by hamster kidney and liver microsomes: implications for the mechanism of estrogen-induced carcinogenesis. Endocrinology 135: 1772-1779.
32. Han X, Liehr JG, (1995) Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: correlation of DNA damage by free radicals with metabolic activation to quinones. Carcinogenesis 16: 2571-2574.
33. Park JH, Mangal D, Frey AJ, Harvey RG, Blair IA, et al. (2009) Aryl hydrocarbon receptor facilitates DNA strand breaks and 8-oxo-2′-deoxyguanosine formation by the aldo-keto reductase product benzo[a]pyrene-7,8-dione. J Biol Chem 284: 29725-29734.
34. Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL, et al. (2008) Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev Res 1: 135-145.
35. Zhang F, Chen Y, Pisha E, Shen L, Xiong Y, et al. (1999) The major metabolite of equilin, 4-hydroxyequilin autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem Res Toxicol 12: 204-213.
36. Shen L, Qiu S, Chen Y, Zhang F, van Breemen RB, et al. (1998) Alkylation of 2′-deoxynucleosides and DNA by the Premarin® metabolite 4-hydroxyequilenin semiquinone radical. Chem Res Toxicol 11: 94-101.
37. Shen L, Pisha E, Huang Z, Pezzuto JM, Krol E, et al. (1997) Bioreductive activation of catechol estrogen-ortho-quinones: aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity. Carcinogenesis 18: 1093-1101.
38. Zhang F, Swanson SM, van Breemen RB, Liu X, Yang Y, et al. (2001) Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol 14: 1654-1659.
39. Chen Y, Liu X, Pisha E, Constantinou AI, Hua Y, et al. (2000) A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol 13: 342-350.
40. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712.
41. Jackson AL, Loeb LA, (2001) The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477: 7-21.
42. Park SA, Na HK, Kim EH, Cha YN, Surh YJ, (2009) 4-hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species. Cancer Res 69: 2416-2424.
43. Dwivedy I, Devanesan P, Cremonesi P, Rogan E, Cavalieri E, (1992) Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem Res Toxicol 5: 828-833.
44. Lareef MH, Garber J, Russo PA, Russo IH, Heulings R, et al. (2005) The estrogen antagonist ICI-182-780 does not inhibit the transformation phenotypes induced by 17-beta-estradiol and 4-OH estradiol in human breast epithelial cells. Int J Oncol 26: 423-429.
45. Fernandez SV, Russo IH, Russo J, (2006) Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int J Cancer 118: 1862-1868.
46. Zahid M, Kohli E, Saeed M, Rogan E, Cavalieri E, (2006) The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem Res Toxicol 19: 164-172.
47. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, et al. (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 94: 10937-10942.
48. Saeed M, Rogan E, Cavalieri E, (2009) Mechanism of metabolic activation and DNA adduct formation by the human carcinogen diethylstilbestrol: the defining link to natural estrogens. Int J Cancer 124: 1276-1284.
49. Saeed M, Higginbotham S, Rogan E, Cavalieri E, (2007) Formation of depurinating N3adenine and N7guanine adducts after reaction of 1,2-naphthoquinone or enzyme-activated 1,2-dihydroxynaphthalene with DNA. Implications for the mechanism of tumor initiation by naphthalene. Chem Biol Interact 165: 175-188.
50. Saeed M, Rogan E, Fernandez SV, Sheriff F, Russo J, et al. (2007) Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. Int J Cancer 120: 1821-1824.
51. Sung JS, Demple B, (2006) Roles of base excision repair subpathways in correcting oxidized abasic sites in DNA. FEBS J 273: 1620-1629.
52. Miller EC, Miller JA, (1981) Mechanisms of chemical carcinogenesis. Cancer 47: 1055-1064.
53. Zahid M, Saeed M, Beseler C, Rogan EG, Cavalieri EL, (2011) Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells. Free Radical Biology and Medicine 50: 78-85.
54. Chen ZH, Hurh YJ, Na HK, Kim JH, Chun YJ, et al. (2004) Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 25: 2005-2013.
55. Liu H, Liu J, van Breemen RB, Thatcher GRJ, Bolton JL, (2005) Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-fluoro substitution prevents quinoid formation. Chem Res Toxicol 18: 162-173.
56. Liu H, Qin Z, Thatcher GRJ, Bolton JL, (2007) Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene. Chem Res Toxicol 20: 1676-1684.
57. Yu B, Qin Z, Wijewickrama GT, Edirisinghe P, Bolton JL, et al. (2009) Comparative methods for analysis of protein covalent modification by electrophilic quinoids formed from xenobiotics. Bioconjug Chem 20: 728-741.
58. Qin Z, Kastrati I, Chandrasena RE, Liu H, Yao P, et al. (2007) Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem 50: 2682-2692.
59. Wang Z, Wijewickrama GT, Peng KW, Dietz BM, Yuan L, et al. (2009) Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus. J Biol Chem 284: 8633-8642.
60. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL, (1996) Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 9: 851-859.
61. Akanni A, Abul-Hajj YJ, (1997) Estrogen-nucleic acid adducts: reaction of 3,4-estrone-o-quinone radical anion with deoxyribonucleosides. 10: 760-766.
62. Akanni A, Tabakovic K, Abul-Hajj YJ, (1997) Estrogen-Nucleic Acid Adducts: Reaction of 3,4-Estrone o-Quinone with Nucleic Acid Bases. 10: 477-481.
63. Akanni A, Abul-Hajj YJ, (1999) Estrogen-Nucleic Acid Adducts: Dissection of the Reaction of 3,4-Estrone Quinone and Its Radical Anion and Radical Cation with Deoxynucleosides and DNA. 12: 1247-1253.
64. Singh R, McEwan M, Lamb JH, Santella RM, Farmer PB, (2003) An improved liquid chromatography/tandem mass spectrometry method for the determination of 8-oxo-7,8-dihydro-2′-deoxyguanosine in DNA samples using immunoaffinity column purification. Rapid Commun Mass Spectrom 17: 126-134.
65. Cuendet M, Liu X, Pisha E, Li Y, Yao J, et al. (2004) Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A cells: differential gene expression. Mutat Res 550: 109-121.
66. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, et al. (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574.